This was followed by the phase 2 BULLSEYE trial, in which patients with oligometastatic prostate cancer with fewer than 5 metastatic sites and who previously received local therapy were randomized to receive up to 4 cycles of [177Lu]Lu-PSMA-617 or active surveillance with deferred treatment (11). This evidence concerns the gene FOLH1 and prostate cancer.